Celyad BE0974260896

CYAD-200 Series – shRNA-based Allogeneic CAR-Ts

1. [verwijderd] 22 november 2019 20:36

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   CYAD-200 Series – shRNA-based Allogeneic CAR-Ts
   
   The Company continues to pursue the development of the proprietary non-gene edited allogeneic shRNA SMARTvector platform and progress towards filing IND applications for the CYAD-200 series of shRNA-based allogeneic CAR-T candidates, including CYAD-211, the Company’s CAR-T therapy targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma.
   
   Bron: www.trivano.com/aandeel/celyad-announ...
2. [verwijderd] 22 november 2019 20:43

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Artikel 13-06-2019
   
   www.genengnews.com/news/celyad-faces-...
3. [verwijderd] 23 november 2019 13:42

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   “ Submission of IND application for CYAD-211 (shRNA-based allogeneic BCMA CAR-T candidate) for the treatment of patients with multiple myeloma is anticipated during first half 2020.”
   
   Bron: www.trivano.com/aandeel/celyad-announ...
   
4. Hautfourno 8 februari 2020 10:25

   auteur info

   • Hautfourno

     Lid sinds: 13 okt 2018

     Laatste bezoek: 19 mei 2022

   • Aanbevelingen

     Ontvangen: 87

     Gegeven: 38

   •    Aantal posts: 204

   The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors.
   
   The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy has also shown no evidence of causing graft-versus-host disease, a condition where foreign immune cells attack the host body.
   
   Celyad’s CAR T-cell immunotherapy is aimed to overcome the drawbacks of CAR T-cell immunotherapies already in the market such as Kymriah and Yescarta. These therapies require immune T-cells to be extracted from patients and transported to labs when they can be genetically modified to fight cancer. This makes manufacturing hard and costly. Celyad’s off-the-shelf CAR-T therapy, on the other hand, would be ready to use in advance.
   
   “Deriving cells from healthy donors as opposed to late-stage cancer patients also means that the yield and quality of harvested cells are higher, which should translate to lower production costs and fewer potential manufacturing failures,” Filippo Petti, CEO of Celyad, told me.
   
   Going forward, another three patients will be enrolled in the first stage of the trial, and further results are expected in early 2020. Celyad then plans to expand the trial in mid-2020, with the total enrollment estimated to reach 36 patients.
   
   car-t immunotherapy celyad off-the-shelf
   There are other off-the-shelf CAR-T therapies in development, such as those of the French company Cellectis. According to David Gilham, Celyad’s VP of Research and Development, Celyad’s technology has a series of key advantages. First, it can target solid tumors. Second, Celyad’s therapy needs only one step to genetically modify its T-cells instead of the several steps that it takes for other companies to modify their T-cells.
   
   While CAR T-cell immunotherapies have revolutionized the treatment of blood cancer, the field as a whole still has a lot of potential in other types of cancer. According to Petti, the development of off-the-shelf options is going to help companies to overcome obstacles to the adoption of cell therapies. These obstacles include high costs and regulatory difficulties in the manufacturing process.